financetom
Business
financetom
/
Business
/
Fleet management firm Vontier's Q2 sales rise 11%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Fleet management firm Vontier's Q2 sales rise 11%
Jul 31, 2025 4:12 AM

Overview

* Vontier ( VNT ) Q2 sales rise 11.1% yr/yr

* Adjusted EPS for Q2 beats consensus at $0.79, per LSEG data

* Co raises full-year adjusted EPS guidance to $3.10-$3.20

Outlook

* Company raises full-year adjusted EPS guidance to $3.10-$3.20

* Vontier ( VNT ) initiates Q3 adjusted EPS guidance of $0.74-$0.78

* Company expects total sales of $3,020-$3,070 mln for 2025

* Vontier ( VNT ) sees adjusted operating profit margin expansion of 20-40bps for 2025

Result Drivers

* CONVENIENCE RETAIL PAYMENT - Strong demand for convenience retail payment solutions contributed to core sales growth

* FUEL DISPENSING EQUIPMENT - Increased demand for above ground fuel dispensing equipment drove Environmental & Fueling Solutions sales

* MACROECONOMIC PRESSURES - Ongoing macroeconomic challenges impacted Repair Solutions segment, affecting discretionary spending

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $773.50 $733.60

mln mln (7

Analysts

)

Q2 Beat $0.79 $0.72 (8

Adjusted Analysts

EPS )

Q2 EPS $0.62

Q2 Net $91.90

Income mln

Q2 $136.40

Operatin mln

g Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the electronic equipment & parts peer group is "buy"

* Wall Street's median 12-month price target for Vontier Corp ( VNT ) is $42.50, about 6.5% above its July 30 closing price of $39.74

* The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
NEO Battery Materials Raises $0.8-Million as it Closes a Private Placement of Share Units
NEO Battery Materials Raises $0.8-Million as it Closes a Private Placement of Share Units
Oct 28, 2024
04:43 PM EDT, 10/28/2024 (MT Newswires) -- NEO Battery Materials ( NBMFF ) after trade Monday said it closed a private placement of share units that raised $0.8 million. The company said it placed two-million units in the financing, with each priced at $0.40 and made up of a share and one half of a two-year warrant to buy a...
CenterPoint Energy's Q3 Non-GAAP Earnings Fall, Revenue Unchanged
CenterPoint Energy's Q3 Non-GAAP Earnings Fall, Revenue Unchanged
Oct 28, 2024
06:49 AM EDT, 10/28/2024 (MT Newswires) -- CenterPoint Energy ( CNP ) reported Q3 non-GAAP earnings Monday of $0.31 per diluted share, down from $0.40 a year earlier. Analysts polled by Capital IQ expected $0.31. Total revenue for the quarter ended Sept. 30 was $1.86 billion, unchanged from a year earlier. Analysts surveyed by Capital IQ expected $1.90 billion. For...
Toyota, NTT to make $3.3 bln R&D investment for AI self-driving, Nikkei reports
Toyota, NTT to make $3.3 bln R&D investment for AI self-driving, Nikkei reports
Oct 28, 2024
Oct 29 (Reuters) - Toyota Motor ( TM ) and Japan's Nippon Telegraph and Telephone ( NPPXF ) will invest 500 billion yen ($3.26 billion) in research and development to create artificial intelligence software to improve self-driving, Nikkei reported on Tuesday. The carmaker and the Tokyo-headquartered telecommunications major are planning to develop automotive software which will use AI to anticipate...
Merck, Moderna Begin Phase 3 Trial of V940, Keytruda Combination
Merck, Moderna Begin Phase 3 Trial of V940, Keytruda Combination
Oct 28, 2024
07:34 AM EDT, 10/28/2024 (MT Newswires) -- Merck ( MRK ) and Moderna ( MRNA ) said Monday it initiated a phase 3 trial evaluating the investigational V940 in combination with Keytruda to treat certain types of non-small cell lung cancer. The first patients in the trial were enrolled in Canada. Price: 104.15, Change: +0.17, Percent Change: +0.16 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved